[go: up one dir, main page]

SG11201705952SA - Heterocyclic compound and pharmaceutical composition comprising same - Google Patents

Heterocyclic compound and pharmaceutical composition comprising same

Info

Publication number
SG11201705952SA
SG11201705952SA SG11201705952SA SG11201705952SA SG11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA
Authority
SG
Singapore
Prior art keywords
same
pharmaceutical composition
heterocyclic compound
heterocyclic
compound
Prior art date
Application number
SG11201705952SA
Inventor
Changhee Min
Byungkyu Oh
Yongeun Kim
Changmin Park
Original Assignee
Beyondbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondbio Inc filed Critical Beyondbio Inc
Publication of SG11201705952SA publication Critical patent/SG11201705952SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201705952SA 2015-02-04 2016-02-02 Heterocyclic compound and pharmaceutical composition comprising same SG11201705952SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150017339 2015-02-04
PCT/KR2016/001133 WO2016126085A2 (en) 2015-02-04 2016-02-02 Heterocyclic compound and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
SG11201705952SA true SG11201705952SA (en) 2017-09-28

Family

ID=56564854

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705952SA SG11201705952SA (en) 2015-02-04 2016-02-02 Heterocyclic compound and pharmaceutical composition comprising same

Country Status (14)

Country Link
US (3) US10227328B2 (en)
EP (1) EP3255042B1 (en)
JP (1) JP6615899B2 (en)
KR (1) KR101783642B1 (en)
CN (1) CN107250130B (en)
AU (1) AU2016216253B2 (en)
BR (1) BR112017016465B1 (en)
CA (1) CA2974788C (en)
DK (1) DK3255042T3 (en)
ES (1) ES2854707T3 (en)
IL (1) IL253538B (en)
RU (1) RU2710743C2 (en)
SG (1) SG11201705952SA (en)
WO (1) WO2016126085A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220130249A (en) 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 EGFR inhibitor compounds
US12391669B2 (en) * 2018-08-30 2025-08-19 The Regents of the University of California et al. Substituted pyrimidines as IRE1 kinase inhibitors
AU2020215684B2 (en) * 2019-01-29 2025-08-21 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
KR20210029693A (en) 2019-09-06 2021-03-16 비욘드바이오주식회사 2,6-Bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and pharmaceutical composition comprising the same
KR102443873B1 (en) * 2019-09-06 2022-09-19 비욘드바이오주식회사 Method for preparing pyrimidinyl bipyridine compound and intermediate therefor
KR102501514B1 (en) 2019-09-06 2023-02-21 비욘드바이오주식회사 2'-Amino-6-(2-amino-6-(1-isopropylpiperidin-4-yl)-5-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol trihydrochloride and pharmaceutical composition comprising the same
KR20210029694A (en) 2019-09-06 2021-03-16 비욘드바이오주식회사 2'-Amino-6-(2-amino-6-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol dihydrochloride and pharmaceutical composition comprising the same
US20230019999A1 (en) * 2019-11-18 2023-01-19 Chugai Seiyaku Kabushiki Kaisha Combination drug
CN111558044B (en) * 2020-06-01 2022-02-11 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Pharmaceutical composition containing sunitinib, and preparation and application thereof
CN116082310B (en) * 2023-02-17 2024-08-20 厦门大学 Bipyridine amide derivatives and their preparation and application
CN116751195B (en) * 2023-06-21 2025-03-07 杭州科兴生物化工有限公司 Bipyridine compound, pharmaceutically acceptable salt thereof, preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
KR100850728B1 (en) * 2000-06-12 2008-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
JP2004534779A (en) * 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド Protein kinase inhibitors for disease treatment
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US7304071B2 (en) * 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CN1742723A (en) 2004-09-02 2006-03-08 天津倍方科技发展有限公司 Medicine composition containing temozolomide-8-carboxylic ether and use of such compound for preparing anti-tumor medicine
WO2008106202A1 (en) * 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
WO2010018458A2 (en) * 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof

Also Published As

Publication number Publication date
CA2974788C (en) 2023-04-11
NZ734084A (en) 2023-09-29
KR101783642B1 (en) 2017-10-10
US10227328B2 (en) 2019-03-12
CN107250130B (en) 2019-11-08
BR112017016465B1 (en) 2023-11-14
CA2974788A1 (en) 2016-08-11
EP3255042A4 (en) 2018-08-01
IL253538A0 (en) 2017-09-28
US20180273510A1 (en) 2018-09-27
US20200190062A1 (en) 2020-06-18
AU2016216253A1 (en) 2017-08-17
US20190135786A1 (en) 2019-05-09
JP6615899B2 (en) 2019-12-04
IL253538B (en) 2020-09-30
KR20160096033A (en) 2016-08-12
EP3255042B1 (en) 2020-12-30
AU2016216253B2 (en) 2019-11-21
RU2017130825A (en) 2019-03-04
JP2018504449A (en) 2018-02-15
CN107250130A (en) 2017-10-13
EP3255042A2 (en) 2017-12-13
DK3255042T3 (en) 2021-02-08
WO2016126085A3 (en) 2016-11-03
US10611754B2 (en) 2020-04-07
RU2710743C2 (en) 2020-01-10
WO2016126085A2 (en) 2016-08-11
RU2017130825A3 (en) 2019-08-12
BR112017016465A2 (en) 2018-06-19
ES2854707T3 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
IL282584A (en) Quinoline derivatives and pharmaceutical compositions containing them
IL258180B (en) Heterocyclic compounds and uses thereof
IL258082B (en) Bezimidazole derivatives and pharmaceutical compositions containing them
ZA201802125B (en) Pharmaceutical composition and application thereof
IL269061A (en) Pharmaceutical composition comprising selexipag
IL271986B1 (en) Pharmaceutical composition
IL247062A0 (en) Heterocyclic compounds , their preparation and compositions pharmaceutical containing them
IL253538A0 (en) Heterocyclic compound and pharmaceutical composition comprising same
PL3287443T3 (en) 6-membered heterocyclic derivative and pharmaceutical composition comprising same
PT3202759T (en) Alpha-aminoamide derivative compound and pharmaceutical composition comprising same
GB201712159D0 (en) Pharmaceutical composition
GB201521462D0 (en) Pharmaceutical composition
HUE068810T2 (en) Pharmaceutical composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
SG10202106375UA (en) Pharmaceutical compositions and use thereof
PL3288933T3 (en) Oxindole compounds and pharmaceutical compositions thereof
GB201515310D0 (en) Pharmaceutical composition
IL254711B (en) Diazepino-indole derivatives and pharmaceutical compositions comprising it
PL3389638T3 (en) Pharmaceutical composition comprising pimobendan
GB201520862D0 (en) Pharmaceutical composition
PL3424500T3 (en) Pharmaceutical composition comprising famitinib
GB201708328D0 (en) Pharmaceutical composition
GB201708329D0 (en) Pharmaceutical composition